The Top 10 Pharmaceutical Companies in India: Growth strategies, performance and SWOT analyses

Table of Contents

Executive summary

• Industry overview
• Cipla
• Ranbaxy
• GSK (India)
• Piramal Healthcare
• Zydus Cadila
• Sun Pharma
• Lupin Laboratories (Lupin)
• Alkem
• Sanofi-Aventis (India)
• Mankind Pharma (Mankind)

Chapter 1 Introduction

• What is this report about?
• Methodology

Chapter 2 Industry overview

• Summary
• Introduction
• Market dynamics
• Indian pharmaceutical market: size and growth
• Key market drivers and resistors
• India' s adoption of product patent regime
• Evolution of biopharmaceuticals in India
• Competitive positioning of India in global pharmaceutical market
• Competitive landscape
• Competitive positioning of the top 10 companies
• Exposure to US generics market
• Comparative analysis of the top 10 companies
• Trends
• Increasing participation of innovator companies in Indian pharmaceutical
• space
• Pharmaceutical companies making inroads into rural India
• Shifting focus towards Japanese generics market
• Growing prevalence of lifestyle diseases
• Expanding alliances in biopharmaceuticals

Chapter 3 Cipla

• Summary
• Company overview
• Marketed products
• Therapeutic focus
• Research and development
• Growth strategies
• Expanding in international markets through alliances and partnerships
• Expanding capabilities
• Growing in the US generics market
• Acquisitions and divestments
• SWOT analysis

Chapter 4 Ranbaxy

• Summary
• Company overview
• Marketed products
• Therapeutic focus
• Research and development
• Growth strategies
• Rebuilding business in the US market
  • Shifting focus towards complex products in the US
  • Monetizing the FTF opportunities in the US
• Improving penetration in emerging markets
• Strengthening management involvement in Ranbaxy
• Acquisitions and divestments
• SWOT analysis

Chapter 5 GSK (India)

• Summary
• Company overview
• Marketed products
• Therapeutic focus
• Research and development
• Growth strategies
• Augmenting product portfolio in India
  • Leveraging its parent company' s product portfolio
  • In-licensing products
• Expanding rural presence and hospital sales
• Acquisitions and divestments
• SWOT analysis

Chapter 6 Piramal Healthcare

• Summary
• Company overview
• Marketed products
• Therapeutic focus
• Research and development
• Growth strategies
• Capitalize on contract manufacturing opportunities
• Growing business through alliances and partnerships
• Acquisitions and divestments
• SWOT analysis

Chapter 7 Zydus Cadila

• Summary
• Company overview
• Marketed products
• Therapeutic focus
• Research and development
• Growth strategies
• Alliances fostering growth in international generics markets
• Sustaining revenue growth in Indian formulation business
• Acquisitions and divestments
• SWOT analysis

Chapter 8 Sun Pharma

• Summary
• Company overview
• Marketed products
• Therapeutic focus
• Research and development
• Growth strategies
• Enhancing presence in the US market
• Focusing on niche segments in developing markets
• Plugging gaps in its business through investments
• Acquisitions and divestments
• SWOT analysis

Chapter 9 Lupin

• Summary
• Company overview
• Marketed products
• Therapeutic focus
• Research and development
• Growth strategies
• Expanding in European markets
• Foray into biosimilars market
• Sustaining growth in the US generics market
• Shifting focus to chronic and specialized products in India
• Acquisitions and divestments
• SWOT analysis

Chapter 10 Alkem

• Summary
• Company overview
• Marketed products
• Therapeutic focus
• Research and development
• Growth strategies
• Expanding presence in nutraceuticals business
• Expansion in international markets
• Acquisitions and divestments
• SWOT analysis

Chapter 11 Sanofi-Aventis (India)

• Summary
• Company overview
• Marketed products
• Therapeutic focus
• Research and development
• Growth strategies
• Leveraging parent company' s product portfolio
• Shifting focus to rural India
• Acquisitions and divestments
• SWOT analysis

Chapter 12 Mankind

• Summary
• Company overview
• Marketed products
• Therapeutic focus
• Research and development
• Growth strategies
• Expanding in international markets
• Investing in pharmaceutical capabilities development
• Foray into fast growing segments
• Acquisitions and divestments
• SWOT analysis

Chapter 13 11 - 20 companies

• Abbott (India)
• Company overview
• Marketed products
• Therapeutic focus
• Research and development

• Dr Reddy' s
• Company overview
• Marketed products
• Therapeutic focus
• Research and development

• Wockhardt
• Company overview
• Marketed products
• Therapeutic focus
• Research and development

• Aristo
• Company overview
• Marketed products
• Therapeutic focus

• Torrent Pharmaceuticals (Torrent)
• Company overview
• Marketed products
• Therapeutic focus
• Research and development

• Pfizer (India)
• Company overview
• Marketed products
• Therapeutic focus
• Research and development

• Intas
• Company overview
• Marketed products
• Therapeutic focus
• Research and development

• Alembic
• Company overview
• Marketed products
• Therapeutic focus
• Research and development

• FDC
• Company overview
• Marketed products
• Therapeutic focus
• Research and development

• Macleods Pharmaceuticals (Macleods)
• Company overview
• Marketed products
• Therapeutic focus
• Research and development

Chapter 14 Appendix

• Glossary
• Index

List of Figures

• Figure 2.1: Indian pharmaceutical market size ($m), 2009 - 14
• Figure 2.2: Key market drivers and resistors of Indian pharmaceutical market
• Figure 2.3: Indian pharmaceutical market SWOT analysis
• Figure 2.4: Top 10 pharmaceutical companies in India market share, 2008
• Figure 2.5: Top 10 pharmaceutical companies in India growth, 2004 - 08
• Figure 2.6: Comparative analysis of the top Indian pharmaceutical companies
• Figure 2.7: Top 10 pharmaceutical companies in India lifestyle segment market share (%), 2008
• Figure 3.8: Cipla therapeutic focus, 2007 - 08
• Figure 3.9: Cipla SWOT analysis
• Figure 4.10: Ranbaxy therapeutic focus, 2007 - 08
• Figure 4.11: Ranbaxy SWOT analysis
• Figure 5.12: GSK (India) therapeutic focus, 2007 - 08
• Figure 5.13: GSK (India) SWOT analysis
• Figure 6.14: Piramal Healthcare therapeutic focus, 2007 - 08
• Figure 6.15: Piramal Healthcare SWOT analysis
• Figure 7.16: Zydus Cadila therapeutic focus, 2007 - 08
• Figure 7.17: Zydus Cadila SWOT analysis
• Figure 8.18: Sun Pharma therapeutic focus, 2007 - 08
• Figure 8.19: Sun Pharma SWOT analysis
• Figure 9.20: Lupin therapeutic focus, 2007 - 08
• Figure 9.21: Lupin SWOT analysis
• Figure 10.22: Alkem therapeutic focus, 2007 - 08
• Figure 10.23: Alkem SWOT analysis
• Figure 11.24: Sanofi-Aventis (India) therapeutic focus, 2007 - 08
• Figure 11.25: Sanofi-Aventis (India) SWOT analysis
• Figure 12.26: Mankind therapeutic focus, 2007 - 08
• Figure 12.27: Mankind SWOT analysis
• Figure 13.28: Abbott (India) therapeutic focus, 2007 - 08
• Figure 13.29: Dr Reddy' s therapeutic focus, 2007 - 08
• Figure 13.30: Wockhardt therapeutic focus, 2007 - 08
• Figure 13.31: Aristo therapeutic focus, 2007 - 08
• Figure 13.32: Torrent therapeutic focus, 2007 - 08
• Figure 13.33: Pfizer (India) therapeutic focus, 2007 - 08
• Figure 13.34: Intas therapeutic focus, 2007 - 08
• Figure 13.35: Alembic therapeutic focus, 2007 - 08
• Figure 13.36: FDC therapeutic focus, 2007 - 08
• Figure 13.37: Macleods therapeutic focus, 2007 - 08

List of Tables

• Table 2.1: Indian pharmaceutical market size ($m), 2009 - 14
• Table 2.2: Novel product pipeline of select Indian biotechnology companies, 2008
• Table 2.3: Major foreign acquisitions by Indian pharmaceutical companies, 2007 - 09
• Table 2.4: Top 10 pharmaceutical companies in India growth (%), 2004 - 08
• Table 2.5: Selected ANDA filings approved in the US, 2009
• Table 2.6: Deals and alliances in Japanese pharmaceutical market, 2007 - 09
• Table 2.7: Selected alliances in the Indian biopharmaceutical market, 2007 - 09
• Table 3.8: Cipla snapshot
• Table 3.9: Cipla top 10 marketed products sales ($m), 2007 - 08
• Table 3.10: Cipla new product launches, 2007 - 08
• Table 3.11: Approved ANDAs of Cipla in the US, 2007 - 09
• Table 4.12: Ranbaxy snapshot
• Table 4.13: Ranbaxy top 10 marketed products sales in India ($m), 2007 - 08
• Table 4.14: Selected Ranbaxy ANDAs with FTF status
• Table 4.15: Ranbaxy acquisitions, 2007 - 09
• Table 5.16: GSK (India) snapshot
• Table 5.17: GSK (India) top 10 marketed products sales ($m), 2007 - 08
• Table 5.18: GSK (India) product launches from parent portfolio, 2007 - 09
• Table 5.19: GSK (India) expected new launches in India, 2009 - 10.
• Table 6.20: Piramal Healthcare snapshot
• Table 6.21: Piramal Healthcare top 10 marketed products sales ($m), 2007 - 08
• Table 6.22: Piramal Healthcare new product launches, 2007 - 08
• Table 6.23: Select Piramal Healthcare' s alliances, 2007 - 09
• Table 6.24: Piramal Healthcare acquisitions, 2007 - 09
• Table 7.25: Zydus Cadila snapshot
• Table 7.26: Zydus Cadila top 10 marketed products sales ($m), 2007 - 08
• Table 7.27: Zydus Cadila R&D collaborations, 2007 - 09
• Table 7.28: Select Zydus Cadila' s alliances, 2005 - 09
• Table 7.29: Zydus Cadila acquisitions, 2007 - 09
• Table 8.30: Sun Pharma snapshot
• Table 8.31: Sun Pharma top 10 marketed products sales ($m), 2007 - 08
• Table 8.32: Sun Pharma new product launches, 2007 - 08
• Table 9.33: Lupin snapshot
• Table 9.34: Lupin top 10 marketed products sales ($m), 2007 - 08
• Table 9.35: Lupin acquisitions, 2007 - 09
• Table 10.36: Alkem snapshot
• Table 10.37: Alkem top 10 marketed products sales ($m), 2007 - 08
• Table 11.38: Sanofi-Aventis (India) snapshot
• Table 11.39: Sanofi-Aventis (India) top 10 marketed products sales ($m), 2007 - 08
• Table 11.40: Sanofi-Aventis (India) key brands launches from parent portfolio
• Table 12.41: Mankind snapshot
• Table 12.42: Mankind top 10 marketed products sales ($m), 2007 - 08
• Table 13.43: Abbott (India) snapshot
• Table 13.44: Abbott (India) top 10 marketed products sales ($m), 2007 - 08
• Table 13.45: Dr Reddy' s snapshot
• Table 13.46: Dr Reddy' s top 10 marketed products sales ($m), 2007 - 08
• Table 13.47: Dr Reddy' s drug development pipeline, 2007 - 08
• Table 13.48: Wockhardt snapshot
• Table 13.49: Wockhardt top 10 marketed products sales ($m), 2007 - 08
• Table 13.50: Aristo snapshot
• Table 13.51: Aristo top 10 marketed products sales ($m), 2007 - 08
• Table 13.52: Torrent snapshot
• Table 13.53: Torrent top 10 marketed products sales ($m), 2007 - 08
• Table 13.54: Pfizer (India) snapshot
• Table 13.55: Pfizer (India) top 10 marketed products sales ($m), 2007 - 08
• Table 13.56: Intas snapshot
• Table 13.57: Intas top 10 marketed products sales ($m), 2007 - 08
• Table 13.58: Alembic snapshot
• Table 13.59: Alembic top 10 marketed products sales ($m), 2007 - 08
• Table 13.60: FDC snapshot
• Table 13.61: FDC top 10 marketed products sales ($m), 2007 - 08
• Table 13.62: Selected FDC new product launches, 2007 - 08
• Table 13.63: Macleods snapshot
• Table 13.64: Macleods top 10 marketed products sales($m), 2007 - 08